Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer

被引:1
|
作者
Estevez, Angela [1 ]
Kaul, Sumedh [2 ]
Fleishman, Aaron [2 ]
Korets, Ruslan [1 ]
Chang, Peter [1 ]
Wagner, Andrew [1 ]
Bellmunt, Joaquim [3 ]
Olumi, Aria F. [1 ]
Rayala, Heidi [1 ]
Gershman, Boris [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Urol Surg, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA USA
[3] Dana Farber Canc Inst, Dept Med, Div Med Oncol, Boston, MA USA
关键词
Bladder cancer; Disparities; BCG; Non-muscle invasive; Carcinoma in situ; GUIDELINES;
D O I
10.1016/j.urolonc.2022.11.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To evaluate the associations of socioeconomic characteristics with the management of non-muscle invasive bladder cancer (NMIBC). Methods: We identified adult patients aged 18 to 89 years with Ta, T1, or Tis NMIBC in the NCDB. We then examined the associations of patient and socioeconomic characteristics with the guidelines-based management of high-risk NMIBC using multivariable logistic regression. Results: 163,949 patients were included in the study cohort, including 64% with Ta, 32% with T1, and 4% with Tis disease. Among those diagnosed with bladder cancer, male (OR 1.24, 95%CI 1.21-1.27), uninsured (OR 1.10, 95%CI 1.01-1.19 vs. private), and non-White (OR 1.34, 95%CI 1.28 -1.41 for Black; OR 1.10; 95%CI 1.03-1.18 for Other vs. White) patients were more likely to be diagnosed with high-risk disease, as well as patients from lower education level areas. Among those with high-risk NMIBC, patients who were older, non-White, Hispanic, uninsured or insured with Medic-aid were less likely to receive guideline recommended intravesical BCG, while those residing in rural and higher education level areas were more likely to receive BCG. When examining non-guidelines based use of radiotherapy for HGT1 disease, older age (OR 1.06; 95% CI 1.04-1.07) and VA/Military insurance (OR 2.73; 95%CI 1.07, 6.98 vs. private) were associated with radiotherapy use. Conclusion: There are strong disparities in the prevalence and management of high-risk NMIBC. These observations highlight impor-tant targets for future strategies to reduce such healthcare disparities and provide more equitable bladder cancer treatment to patients. ? 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:255e15 / 255e21
页数:7
相关论文
共 50 条
  • [1] Current approaches for identifying high-risk non-muscle invasive bladder cancer
    Sanli, Oner
    Lotan, Yair
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (03) : 223 - 235
  • [2] Emerging therapies in the management of high-risk non-muscle invasive bladder cancer (HRNMIBC)
    Werntz, Ryan P.
    Adamic, Brittany
    Steinberg, Gary D.
    WORLD JOURNAL OF UROLOGY, 2019, 37 (10) : 2031 - 2040
  • [3] The Promise of Radiotherapy in High-Risk Non-Muscle Invasive Bladder Cancer
    Bola, Becky
    Hoskin, Peter J.
    Sangar, Vijay
    Choudhury, Ananya
    CANCERS, 2025, 17 (04)
  • [4] Genomic characterization of high-risk non-muscle invasive bladder cancer
    Meeks, Joshua J.
    Carneiro, Benedito A.
    Pai, Sachin G.
    Oberlin, Daniel T.
    Rademaker, Alfred
    Fedorchak, Kyle
    Balasubramanian, Sohail
    Elvin, Julia
    Beaubier, Nike
    Giles, Francis J.
    ONCOTARGET, 2016, 7 (46) : 75176 - 75184
  • [5] Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer
    Al Awamlh, Bashir Al Hussein
    Chang, Sam S.
    CURRENT ONCOLOGY REPORTS, 2023, 25 (02) : 83 - 91
  • [6] Immunotherapy of High Risk Non-Muscle Invasive Bladder Cancer
    Ahdoot, Michael
    Theodorescu, Dan
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (11) : 1345 - 1352
  • [7] New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer
    Asimakopoulos, Anastasios D.
    Kochergin, Maxim
    Colalillo, Gaia
    Fahmy, Omar
    Hassan, Fahmy
    Renninger, Markus
    Gallioli, Andrea
    Gavrilov, Pavel
    Gakis, Georgios
    BLADDER CANCER, 2023, 9 (03) : 237 - 251
  • [8] Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
    Karsten Zieger
    Carsten Wiuf
    Klaus Møller-Ernst Jensen
    Torben Falck Ørntoft
    Lars Dyrskjøt
    BMC Cancer, 9 (1)
  • [9] Incidence, initial management and survival of high-risk non-muscle invasive bladder cancer in Northern France
    Saint, Fabien
    Pasquier, David
    Villers, Arnauld
    Massa, Jordan
    Colin, Pierre
    Vankemmel, Olivier
    Leroy, Xavier
    Bonnal, Jean-Louis
    Plouvier, Sandrine D.
    FRENCH JOURNAL OF UROLOGY, 2024, 34 (09):
  • [10] Effectiveness of Early Radical Cystectomy for High-Risk Non-Muscle Invasive Bladder Cancer
    Diamant, Elliott
    Roumiguie, Mathieu
    Ingels, Alexandre
    Parra, Jerome
    Vordos, Dimitri
    Bajeot, Anne-Sophie
    Chartier-Kastler, Emmanuel
    Soulie, Michel
    de la Taille, Alexandre
    Roupret, Morgan
    Seisen, Thomas
    CANCERS, 2022, 14 (15)